Jeff Liter, CEO of Luminary, discusses his company’s approach to CAR-T therapies and why the developing Saudi market has ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

The supplemental premarket approval application is supported by Phase III data, which showed significant improvements in neck ...

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...

Gamifant marks the first-ever FDA-approved treatment for both adult and pediatric patients with hemophagocytic ...

William Shatner endorsed Tinnitus Quest, a nonprofit seeking to promote new treatments and a cure for the condition. Yet, ...

Weight Watchers is Novo Nordisk's latest partnersip.

In response to the rising importance of real-world evidence (RWE) in showing value to payers beyond traditional clinical ...

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions.

Pedro Valencia, VP, asset strategy, leadership, oncology, AbbVie, outlines how the company is accelerating development across ...

Pharmaceutical Executive: How is federal policy reshaping life sciences investments? John Stanford: Federal policy is ...

Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...